Abstract
PurposeTo evaluate the reliability of ultrasound hepatorenal index (US-HRI) and magnetic resonance imaging proton density fat fraction (MRI-PDFF) techniques in the diagnosis of hepatic steatosis, with magnetic resonance spectroscopy proton density fat fraction (MRS-PDFF) as the reference standard.Materials and methodsFifty-two adult volunteers (30 men, 22 women; age, 31.5 ± 6.5 years) who had no history of kidney disease or viral/alcoholic hepatitis were recruited to undergo abdominal US, MRI, and MRS examinations. US-HRI was calculated from the average of three pairs of regions of interest (ROIs) measurements placed in the liver parenchyma and right renal cortex. On MRI, the six-point Dixon technique was employed for calculating proton density fat fraction (MRI-PDFF). An MRS sequence with a typical voxel size of 27 ml was chosen to estimate MRS-PDFF as the gold standard. The data were evaluated using Pearson’s correlation coefficient and receiver operating characteristic (ROC) curves.ResultsThe Pearson correlation coefficients of US-HRI and MRI-PDFF with MRS-PDFF were 0.38 (p = 0.005) and 0.95 (p<0.001), respectively. If MRS-PDFF ≥5.56% was defined as the gold standard of fatty liver disease, the areas under the curve (AUCs), cut-off values, sensitivities and specificities of US-HRI and MRI-PDFF were 0.74, 1.54, 50%, 91.7% and 0.99, 2.75%, 100%, 88.9%, respectively. The intraclass correlation coefficients (ICCs) of US-HRI and MRI-PDFF were 0.70 and 0.85.ConclusionMRI-PDFF was more reliable than US-HRI in diagnosing hepatic steatosis.
Highlights
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder
NAFLD is considered an important cause of fibrosis progression, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) [2]
The purpose of this study was to evaluate the reliabilitiy of fat quantification by US (US-HRI) and MRI-PDFF techniques in the diagnosis of hepatic steatosis, with magnetic resonance spectroscopy (MRS)-PDFF as the reference standard
Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder. A meta-analysis reported a prevalence of 24% in the worldwide population [1]. NAFLD is considered an important cause of fibrosis progression, nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC) [2]. NAFLD has shown a strong association with coronary artery disease, osteoporosis, metabolic syndrome [3], and rheumatoid arthritis [4]. The prevalence of NAFLD varies with age, gender, and weight status [5]. Detection and quantification of hepatic steatosis play an important role in treatment because NAFLD can be treated by control of diabetes, weight loss or lifestyle modification [6]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.